Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

Efficacy and tolerability of lumiracoxib, a highly selective cyclo-oxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis

Authors Piet Geusens, Willem Lems

Published 11 April 2008 Volume 2008:4(2) Pages 337—344


Piet Geusens1, Willem Lems2

1Department of Internal Medicine, Subdivision of Rheumatology, University Hospital, Maastricht, The Netherlands and Biomedical Research Institute, University Hasselt, Belgium; 2Vrije Universiteit Medical Centre, Department of Rheumatology, Amsterdam, the Netherlands

Abstract: Lumiracoxib is a COX2 inhibitor that is highly selective, is more effective than placebo on pain in osteoarthritis (OA), with similar analgesic and anti-inflammatory effects as non-selective NSAIDs and the selective COX2 inhibitor celecoxib, has a lower incidence of upper gastrointestinal (GI) side effects in patients not taking aspirin, and a similar incidence of cardiovascular (CV) side effects compared to naproxen or ibuprofen. In the context of earlier guidelines and taking into account the GI and CV safety results of the TARGET study, lumiracoxib had secured European Medicines Agency (EMEA) approval with as indication symptomatic treatment of OA as well as short-term management of acute pain associated with primary dysmenorrhea and following orthopedic or dental surgery. In the complex clinical context of efficiency and safety of selective and non-selective COX inhibitors, its prescription and use should be based on the risk and safety profile of the patient. In addition, there is further need for long-term GI and CV safety studies and general post-marketing safety on its use in daily practice. Meanwhile, at the time of submission of this manuscript, the EMEA has withdrawn lumiracoxib throughout Europe because of the risk of serious side effects affecting the liver.

Keywords: lumiracoxib, NSAIDs, COX2 inhibitors, gastro-intestinal and cardiovascular safety

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

First experience with the new high-frequency femtosecond laser system (LDV Z8) for cataract surgery

Pajic B, Vastardis I, Gatzioufas Z, Pajic-Eggspuehler B

Clinical Ophthalmology 2014, 8:2485-2489

Published Date: 8 December 2014

Current guidelines for high-density lipoprotein cholesterol in therapy and future directions

Subedi BH, Joshi PH, Jones SR, Martin SS, Blaha MJ, Michos ED

Vascular Health and Risk Management 2014, 10:205-216

Published Date: 8 April 2014

A characteristic optic disc appearance associated with myopia in subjects with Graves' ophthalmopathy and in subjects with primary open-angle glaucoma

Yamazaki S, Inoue R, Tsuboi T, Kozaki A, Inoue T, Inoue T, Inoue Y

Clinical Ophthalmology 2013, 7:47-53

Published Date: 7 January 2013

Estimating glomerular filtration rate in a population-based study

Anoop Shankar, Kristine E Lee, Barbara EK Klein, et al

Vascular Health and Risk Management 2010, 6:619-627

Published Date: 16 July 2010

Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study

JP Baguet, R Asmar, P Valensi, S Nisse-Durgeat, JM Mallion

Vascular Health and Risk Management 2009, 5:175-183

Published Date: 21 January 2009

Hydrophobic bile acids, genomic instability, Darwinian selection, and colon carcinogenesis

Claire M Payne, Carol Bernstein, Katerina Dvorak, Harris Bernstein

Clinical and Experimental Gastroenterology 2008, 1:19-47

Published Date: 16 December 2008

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review

Ashish Chandwani, Jonathan Shuter

Therapeutics and Clinical Risk Management 2008, 4:1023-1033

Published Date: 10 October 2008

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)

Martin Henkes, Heiko van der Kuip, Walter E Aulitzky

Therapeutics and Clinical Risk Management 2008, 4:163-187

Published Date: 8 February 2008

A critical analysis of barriers to the clinical implementation of pharmacogenomics

Ross A McKinnon, Michael B Ward, Michael J Sorich

Therapeutics and Clinical Risk Management 2007, 3:751-759

Published Date: 15 November 2007